Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



A nanoscale, biocompatible and amphiphilic prodrug of cabazitaxel with improved anticancer efficacy against 3D spheroids of prostate cancer cells

Author affiliations

Abstract

Chemotherapy is still a major therapeutic approach for the treatment of cancer. Cabazitaxel (CTX) is a highly effective anticancer drug for the treatment of prostate cancer. However, insolubility in water and non-specific drug delivery are major challenges in its application. In this study, we have designed pH-responsive and water-soluble prodrugs of CTX using pluronic F68 and pH-sensitive linkers for its site-specific delivery. The synthesized pluronic F68–CTX conjugates (F68–SA–CTX via a succinoyl linker; and F68–CAA–CTX via a cis-aconityl linker) were characterized through 1H-NMR and FTIR analysis. The nanomicelles of the amphiphilic prodrugs of CTX were self-assembled in water and demonstrated a low critical micelle concentration, a particle size of about 95 nm, monodispersity, spherical shape, and pH-responsive stability. Comparatively, cis-aconityl linker-based nanomicelles exhibited better pH-responsiveness and control over the release of CTX in comparison to succinoyl linker-based nanomicelles. Furthermore, the cis-aconityl linked nanomicelles showed greater inhibition of growth of human prostate cancer cells, stimulated higher ROS generation, decreased mitochondrial membrane potential and induced greater apoptosis without changing the cell cycle arrest mechanism of CTX. Thus, the present prodrug formulation of CTX is more advantageous than its conventional formulation.

Graphical abstract: A nanoscale, biocompatible and amphiphilic prodrug of cabazitaxel with improved anticancer efficacy against 3D spheroids of prostate cancer cells

Back to tab navigation

Supplementary files

Article information


Submitted
10 Apr 2020
Accepted
01 Jun 2020
First published
01 Jun 2020

This article is Open Access

Mater. Adv., 2020, Advance Article
Article type
Paper

A nanoscale, biocompatible and amphiphilic prodrug of cabazitaxel with improved anticancer efficacy against 3D spheroids of prostate cancer cells

A. K. Jangid, D. Pooja, P. Jain, S. V. K. Rompicharla, S. Ramesan and H. Kulhari, Mater. Adv., 2020, Advance Article , DOI: 10.1039/D0MA00189A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material and it is not used for commercial purposes.

Reproduced material should be attributed as follows:

  • For reproduction of material from NJC:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
  • For reproduction of material from PCCP:
    [Original citation] - Published by the PCCP Owner Societies.
  • For reproduction of material from PPS:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
  • For reproduction of material from all other RSC journals:
    [Original citation] - Published by The Royal Society of Chemistry.

Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.


Social activity

Search articles by author

Spotlight

Advertisements